A clinical trial of KP484

Trial Profile

A clinical trial of KP484

Planning
Phase of Trial: Phase I

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs KP-484 (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Nov 2017 According to a KemPharm media release, this study is anticipated to be initiated in 2018.
    • 02 Nov 2017 According to a KemPharm media release, Investigational New Drug (IND) application has been approved.
    • 22 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top